Labcorp (LH) has announced the expansion of its molecular bioanalytical laboratory in Greenfield, IN. The expanded facility will increase the company’s global molecular bioanalytical capacity, enabling the company to help biopharmaceutical customers bring life-saving advanced therapies to patients faster.The latest development is expected to positively boost the company’s Central Laboratories business under the Biopharma Laboratory Services (“BLS”) segment.Predicting LH Stock Movement Following the NewsSinc ...

The American College of Obstetricians and Gynecologists (ACOG) recommends postpartum care be treated as an ongoing process rather than a single doctor's visit. However, estimates suggest that a significant number of women do not attend even one postpartum appointment, in part due to access barriers like lack of health insurance, transportation and childcare."The postpartum period is a precarious time for women in the United States. Current standards of care provide insufficient support for women who may be ...

Labcorp Holdings Inc. (LH) recently announced the completion of its acquisition of select assets of BioReference Health — a wholly-owned subsidiary of OPKO Health, Inc. (OPK). The transaction is aimed at providing customers with greater access to Labcorp's comprehensive, high-quality laboratory services, scientific expertise and expanded testing capabilities in key regions across the United States.Likely Trend of LH Stock Following the NewsFollowing the announcement, shares of Labcorp rose 2.1% to $225.76 y ...

BURLINGTON, N.C., Sept. 16, 2024 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH) (Labcorp) announced today that its wholly owned subsidiary, Laboratory Corporation of America Holdings (LCAH), has priced its offering of $2,000,000,000 in senior notes (the Offering). The Offering consists of three tranches: $650,000,000 aggregate principal amount of 4.350% Senior Notes due 2030 (the 2030 Notes), $500,000,000 aggregate principal amount of 4.550% Senior Notes due 2032 (the 2032 Notes) and $850,000,000 aggregate ...

Enhances Labcorp's laboratory services network and expands access to its clinical services BURLINGTON, N.C. and MIAMI, Sept. 16, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (Nasdaq: OPK), a multinational biopharmaceutical and diagnostics company, announced today the completion of Labcorp's acquisition of select assets of BioReference Health, a wholly owned subsidiary of OPKO Health. The transaction is expected to provide ...

Labcorp Holdings, Inc. (LH) has been benefiting from the solid execution of its strategic priorities. Investments in targeted high-growth areas are expected to continue the momentum. The company faces headwinds from macroeconomic uncertainties and growing foreign exchange issues. The stock carries a Zacks Rank #3 (Hold) currently.Factors Driving LH StockAs part of its expansion efforts, Labcorp is focusing more on key growth areas such as oncology, women’s health, autoimmune disease and neurology. The compa ...

Labcorp (LH) has announced a strategic collaboration with Ballad Health to provide outreach laboratory services across the Appalachian Highlands region. Under the agreement, the company will acquire select operating assets of Ballad Health’s outreach lab services, which, combined with their ongoing partnership, aim to enhance patient care, expand access to advanced testing and improve efficiency for the health system and its patients.The companies expect to close the transaction in December 2024, subject to ...

Laboratory Corporation of America Holdings (LH) , or Labcorp, is poised for growth in the upcoming quarters due to its series of strategic acquisitions and partnerships. The company is nearing its targeted savings for the Launchpad business process improvement initiative by the end of 2024. Additionally, its strong emphasis on high-growth sectors like oncology, women’s health and neurology paves the way for substantial market gains.Meanwhile, unfavorable solvency and the adverse impacts of macroeconomic cha ...

Labcorp (LH) has been benefiting from the solid execution of its strategic priorities. Investment in targeted high-growth areas should continue to drive the momentum. The company faces headwinds from macroeconomic uncertainties and currency translations. The stock carries a Zacks Rank #3 (Hold) currently.As part of its expansion efforts, Labcorp is focusing more on key growth areas such as oncology, women’s health, autoimmune disease and neurology. The company’s ability to develop, license and ultimately sc ...

收入增长 - 公司2024年上半年收入为63.975亿美元，同比增长5.4%[105] - 公司2024年第二季度总收入为32.209亿美元，同比增长6.2%[108] - 2024年第二季度Dx业务收入为25.249亿美元，同比增长7.9%[107] - 2024年第二季度BLS业务收入为7.07亿美元，同比增长1.1%[107] - 2024年第二季度Dx业务有机增长为4.7%，主要由Base Business增长5.6%推动[109] - 2024年第二季度Dx业务有机体积增长为2.9%，总体积增长为5.7%[109] - 2024年第二季度BLS业务有机增长为1.2%[109] - 公司2024年上半年总收入为6397.5百万美元，较2023年同期增长5.4%[137] - Dx部门的运营收入从去年的851.2亿美元增加到今年的859.4亿美元，增加了0.9%[162] - BLS部门的运营收入从去年的178.2亿美元增加到今年的207.3亿美元，增加了16.3%[162] 成本和费用 - 公司2024年第二季度成本费用为2294.5百万美元，较2023年同期增长4.7%[111] - 公司2024年第二季度销售、一般和管理费用为557.8百万美元，较2023年同期增长10.3%[114] - 公司2024年第二季度无形资产和其他资产摊销为62.2百万美元，较2023年同期增长20.8%[117] - 公司2024年第二季度重组和其他费用为11.6百万美元，较2023年同期减少26.3%[121] - 公司2024年第二季度利息费用为47.6百万美元，较2023年同期减少4.4%[123] - 公司2024年第二季度其他净收入为19.5百万美元，较2023年同期增长215.0%[127] - 公司2024年第二季度所得税费用为62.1百万美元，较2023年同期增长24.7%[129] - 公司记录了与停用的机器人资产相关的减值费用2.5亿美元[150] - 公司记录了资本化软件成本和其他无形资产的减值费用5亿美元[150] - 公司记录了重组和其他费用16.6亿美元，相比去年同期的23.3亿美元减少了28.6%[151] - 公司的利息费用从去年的100.5亿美元减少到今年的94.5亿美元，减少了6.0%[153] - 公司的其他净收入从去年的-23.8亿美元增加到今年的39.5亿美元，增加了265.7%[156] - 公司的所得税费用从去年的113.7亿美元增加到今年的131.2亿美元，增加了15.4%[158] 业务部门调整 - 公司已完成Fortrea的分离，该分离预计对公司及其股东在联邦所得税方面是免税的[104] - 公司重新调整了业务部门，将之前的Drug Development部门更名为Biopharma Laboratory Services部门[104] 风险和合规 - 公司面临多项风险，包括政府和第三方支付者的法规变化、反欺诈和滥用法律的执行、隐私和安全法规的遵守、实验室许可证的损失或暂停等[100] 财务表现 - 公司2024年第二季度Dx部门营业利润为441.5百万美元，较2023年同期增长7.8%[133] - 公司2024年第二季度BLS部门营业利润为107.4百万美元，较2023年同期增长2.7%[133] 外汇和汇率管理 - 公司2024年上半年收入中约13.7%和2023年上半年收入中约13.6%是以美元以外的货币计价的[175] - 假设所有外币对美元的平均汇率变动10%，将影响2024年上半年税前利润约13.5亿美元[175] - 截至2024年6月30日，公司持有10份外币远期合约，名义总值约361.0亿美元，到期日为2024年7月；截至2023年12月31日，持有9份外币远期合约，名义总值约305.8亿美元，到期日为2024年1月[175] - 公司参与了总额为600.0亿美元的美元对瑞士法郎交叉货币互换协议，其中300.0亿美元于2031年到期，300.0亿美元于2034年到期[176] - 公司通过固定和浮动利率债务的适当组合以及使用衍生金融工具（主要是利率互换）来管理利率风险和整体借款成本[177] - 公司于2021年5月签订了名义总值为500.0亿美元的固定对浮动利率互换协议，用于对冲长期债务公允价值变动，利率基于三个月SOFR加1.0706%[178] 现金和投资 - 公司的现金及现金等价物从去年的1930.6亿美元减少到今年的265.1亿美元[166] - 公司宣布了新的股票回购计划，授权回购高达1430.4亿美元的股票[170]